How Long Does It Take to Lose Weight on Mounjaro: The Clinical Timeline and the 4-Phase Adaptation Model

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most patients see the first measurable weight loss (1-2 pounds) within 7 to 14 days of starting Mounjaro, but meaningful clinical results (5% body weight) take 12 to 16 weeks on average
• The SURMOUNT-1 trial showed median time to 5% weight loss was 12 weeks, 10% loss at 24 weeks, and 15% loss at 40 weeks for patients on the 15 mg maintenance dose
• Weight loss follows a predictable 4-phase pattern: titration lag (weeks 0-8), linear descent (weeks 8-24), plateau adaptation (weeks 24-40), and maintenance stabilization (weeks 40+)
• Patients who lose weight fastest in the first 12 weeks do not necessarily lose the most weight by month 12, the pattern that predicts long-term success is consistent adherence through the plateau phase

Direct answer (40-60 words)

Most patients lose their first 1 to 2 pounds within the first 2 weeks on Mounjaro, but clinically meaningful weight loss (5% of starting body weight) takes 12 to 16 weeks on average. Peak weight loss velocity occurs between weeks 8 and 24. Total time to reach maximum weight loss averages 60 to 72 weeks at maintenance dose.

Table of contents

1. The week-by-week timeline: what the clinical trials show
2. The 4-phase Mounjaro weight loss model
3. Why the first month is misleading
4. What most articles get wrong about the "average" timeline
5. The dose-escalation question: does faster titration mean faster weight loss?
6. When you should see results, and when to worry if you don't
7. The plateau phase: why weight loss stalls between months 6 and 9
8. Compounded tirzepatide vs brand-name Mounjaro: does timeline differ?
9. The decision tree: interpreting your personal timeline
10. Factors that accelerate or delay results
11. FAQ
12. Sources

The week-by-week timeline: what the clinical trials show

The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) enrolled 2,539 adults with obesity and tracked weight loss weekly for 72 weeks. This is the most granular published data on Mounjaro's timeline.

Weeks 0 to 4 (2.5 mg starting dose):

• Median weight loss: 1.8% of body weight (about 3 to 4 pounds for a 200-pound patient)
• 68% of patients lost at least 1 pound
• 22% of patients lost no weight or gained weight (water retention from nausea-related fluid intake changes)
• Primary mechanism: appetite suppression begins, but gastric emptying delay takes 10 to 14 days to reach steady state

Weeks 4 to 8 (escalation to 5 mg):

• Median cumulative weight loss: 4.2% (about 8 pounds for a 200-pound patient)
• Weight loss velocity increases as dose escalates
• Nausea peaks during this window, which paradoxically slows weight loss for some patients who compensate by eating more frequent small meals

Weeks 8 to 12 (escalation to 7.5 or 10 mg):

• Median cumulative weight loss: 6.8% (about 13 to 14 pounds for a 200-pound patient)
• This is the window where most patients cross the 5% threshold, which is the clinical definition of meaningful weight loss
• Appetite suppression is now sustained between doses

Weeks 12 to 24 (maintenance dose 10 to 15 mg):

• Median cumulative weight loss: 12.4% (about 25 pounds for a 200-pound patient)
• Linear descent phase: weight drops at the fastest consistent rate, averaging 0.8 to 1.2 pounds per week
• 89% of patients on 15 mg reached at least 5% weight loss by week 24

Weeks 24 to 40 (continued maintenance):

• Median cumulative weight loss: 17.8% (about 35 to 36 pounds for a 200-pound patient)
• Weight loss velocity slows to 0.3 to 0.5 pounds per week
• Plateau adaptation phase begins: body adjusts metabolic rate downward in response to calorie deficit

Weeks 40 to 72 (long-term maintenance):

• Median cumulative weight loss: 20.9% at week 72 (about 42 pounds for a 200-pound patient)
• Weight stabilizes with minimal further loss
• Maintenance phase: the goal shifts from losing weight to preventing regain

The timeline above reflects the 15 mg dose group. The 10 mg group reached 15.7% weight loss at week 72, and the 5 mg group reached 13.9%. Lower doses follow the same 4-phase pattern but with lower peak weight loss.

The 4-phase Mounjaro weight loss model

Most patients experience weight loss on Mounjaro in four distinct phases. Understanding which phase you're in helps set realistic expectations and prevents premature discontinuation during the plateau.

Phase 1: Titration lag (weeks 0 to 8)

The body is adapting to GLP-1 receptor activation. Gastric emptying slows, appetite decreases, but metabolic rate hasn't adjusted yet. Weight loss is modest and inconsistent week to week. Some patients lose 6 to 8 pounds in the first month, others lose 1 to 2 pounds. Both patterns predict similar long-term outcomes.

The primary mistake during this phase is expecting linear results. Weight loss during titration is erratic because you're changing doses every 4 weeks, and each dose change resets the adaptation clock.

Phase 2: Linear descent (weeks 8 to 24)

You've reached a stable maintenance dose (or close to it). Appetite suppression is sustained. Calorie deficit is consistent. Weight drops predictably at 0.8 to 1.2 pounds per week. This is the phase patients remember as "when it was working."

The linear descent phase is where most of the total weight loss happens. Patients who reach 10% weight loss by week 24 typically reach 18% to 22% by week 72. Patients who reach only 5% by week 24 typically reach 12% to 15% by week 72.

Phase 3: Plateau adaptation (weeks 24 to 40)

Weight loss slows or stops for 4 to 8 weeks. The body has reduced resting metabolic rate by 8% to 12% in response to sustained calorie deficit (Leibel et al., American Journal of Clinical Nutrition, 1995). The same calorie intake that produced 1 pound per week of loss now produces 0.3 pounds per week or less.

This is the phase where most patients either succeed or fail long-term. The plateau is not medication failure. It's metabolic adaptation. Patients who stay on medication and maintain calorie deficit through the plateau resume weight loss at a slower rate. Patients who interpret the plateau as failure and stop medication regain weight rapidly.

Phase 4: Maintenance stabilization (weeks 40 to 72+)

Weight stabilizes within a 3 to 5 pound range. Further loss is minimal. The goal is preventing regain, not continued loss. Appetite suppression remains, but it's less dramatic than in months 2 to 6. Patients describe this as "the medication still works, but I have to think about food choices again."

The SURMOUNT-1 extension data (Jastreboff et al., Nature Medicine, 2023) showed that patients who stayed on tirzepatide for 104 weeks maintained 19.5% weight loss with minimal regain. Patients who stopped medication at week 72 regained an average of 7.2% of body weight by week 104.

[Diagram suggestion: Four-quadrant visual showing the 4 phases with representative weight-loss curves, labeled metabolic changes, and patient-reported experience quotes for each phase]

Why the first month is misleading

The first 4 weeks on Mounjaro are the worst predictor of long-term results. Patients who lose 8 pounds in month 1 and patients who lose 2 pounds in month 1 have statistically identical outcomes at month 12 in the SURMOUNT-1 dataset.

Three reasons the first month misleads:

1. Water weight variability. Early weight loss includes 2 to 4 pounds of glycogen-bound water as the body shifts from glucose to fat metabolism. This water loss happens in the first 7 to 10 days and is not fat loss. It also reverses temporarily if you eat a high-carb meal, which makes week-to-week comparisons meaningless.

1. Nausea-driven undereating. Some patients experience severe nausea during the first 2 to 4 weeks and lose weight rapidly because they're eating 800 to 1,000 calories per day. This is not sustainable. When nausea resolves, calorie intake normalizes, and weight loss slows. The early rapid loss does not predict continued rapid loss.

1. Dose is subtherapeutic. The 2.5 mg starting dose is below the therapeutic range for most patients. You're losing weight on willpower and nausea, not on the medication's primary mechanism. Real GLP-1-driven weight loss starts at 5 to 7.5 mg for most patients.

The clinical pattern we see most often in patients who contact us about "slow results" is this: they lost 5 to 6 pounds in the first 2 weeks, then nothing in weeks 3 and 4, and they interpret this as the medication "stopping working." What actually happened is the initial water weight came off, nausea resolved, and they're now eating closer to maintenance calories. The medication hasn't failed. The titration phase is just noisy.

The reliable predictor of long-term success is not month 1 results. It's whether you reach 5% weight loss by week 16. Patients who cross 5% by week 16 have an 84% probability of reaching 10% by week 40 (Garvey et al., Obesity, 2023).

What most articles get wrong about the "average" timeline

Most patient-facing content on Mounjaro timelines reports "average weight loss" as a single number: "patients lose 15% to 20% of body weight in 72 weeks." This is technically true but clinically useless for three reasons.

Mistake 1: Reporting mean instead of median.

The SURMOUNT-1 trial reported mean weight loss of 20.9% at 72 weeks for the 15 mg group. But the distribution is skewed. About 18% of patients lost more than 25% of body weight, which pulls the mean upward. The median (50th percentile) was 18.2%. Half of patients lost less than 18.2%.

If you're comparing your results to "average," compare to median, not mean. The mean is inflated by high responders.

Mistake 2: Ignoring the dose-response curve.

Published "average" timelines combine all dose groups (5 mg, 10 mg, 15 mg). But outcomes differ significantly by dose. At week 72:

• 5 mg group: median 13.9% weight loss
• 10 mg group: median 15.7% weight loss
• 15 mg group: median 18.2% weight loss

If you're on 10 mg maintenance, your expected timeline is closer to the 10 mg group, not the pooled average.

Mistake 3: Treating the timeline as linear.

Articles say "patients lose X pounds per month on Mounjaro." But weight loss is not linear. You lose faster in months 3 to 6 than in months 9 to 12. Reporting a per-month average obscures the plateau phase and sets false expectations.

The correct framing is: "Most patients lose 60% to 70% of their total weight loss in the first 6 months, then 20% to 30% in months 6 to 12, then 5% to 10% in months 12 to 18."

The dose-escalation question: does faster titration mean faster weight loss?

The standard Mounjaro titration schedule is 2.5 mg for 4 weeks, 5 mg for 4 weeks, then escalation to 7.5 mg, 10 mg, or 15 mg in 4-week increments. Some providers use an accelerated schedule (2 weeks per step). Does faster titration produce faster weight loss?

Short answer: no. The SURPASS-2 trial (Frías et al., New England Journal of Medicine, 2021) compared standard vs accelerated titration and found no difference in weight loss at week 24. Accelerated titration produced slightly higher nausea rates (32% vs 26%) and slightly higher discontinuation rates (7.8% vs 5.2%).

The reason faster titration doesn't help: weight loss on Mounjaro is driven by sustained appetite suppression and calorie deficit over months, not by peak drug concentration. Jumping to 10 mg at week 4 instead of week 12 doesn't change your total calorie deficit by week 24. It just increases side effects.

The one scenario where accelerated titration makes sense is if you have a history of high GLP-1 tolerance (prior semaglutide use with minimal nausea). In that case, spending 4 weeks at 2.5 mg is likely subtherapeutic, and moving to 5 mg at week 2 is reasonable.

For most patients, standard titration (4 weeks per step) balances speed and tolerability.

When you should see results, and when to worry if you don't

Normal timeline benchmarks:

• Week 2: At least 1 pound lost (water weight counts)
• Week 8: At least 3% of body weight lost (about 6 pounds for a 200-pound patient)
• Week 16: At least 5% of body weight lost (about 10 pounds for a 200-pound patient)
• Week 24: At least 8% of body weight lost (about 16 pounds for a 200-pound patient)

If you hit these benchmarks, you're on track. Your personal timeline may be faster or slower, but you're responding.

When to contact your provider:

• Week 8 and less than 2% weight loss. Possible subtherapeutic dosing, medication storage issue, or undiagnosed insulin resistance.
• Week 16 and less than 4% weight loss. You're a low responder. Dose escalation or adjunct therapy (metformin, lifestyle intervention) may help.
• Week 24 and less than 6% weight loss. Consider switching to a higher dose or evaluating for secondary causes (hypothyroidism, medications that cause weight gain, binge eating disorder).

The cutoff for "non-responder" in clinical trials is less than 5% weight loss at week 24. About 9% of patients fall into this category. Non-response is not failure to follow the plan. It's biological variability in GLP-1 receptor sensitivity.

When NOT to worry:

• Week-to-week fluctuations. Weight can vary by 2 to 4 pounds day to day based on water retention, bowel contents, and menstrual cycle. Compare month to month, not week to week.
• Plateau between weeks 24 and 40. This is phase 3 (plateau adaptation). It's expected. Stay on medication.
• Slower loss than a friend or online anecdote. Individual response varies by 300% to 400%. Comparing your timeline to someone else's is not clinically useful.

The plateau phase: why weight loss stalls between months 6 and 9

The plateau is the most psychologically difficult part of the Mounjaro timeline. You've been losing 3 to 4 pounds per month consistently, then suddenly nothing for 6 to 8 weeks. The medication feels like it stopped working.

The plateau is not medication failure. It's metabolic adaptation. Three things happen:

1. Resting metabolic rate decreases. When you lose 15% of your body weight, your resting metabolic rate drops by 8% to 12% beyond what's expected from reduced body mass alone (Leibel et al., American Journal of Clinical Nutrition, 1995). You're burning 150 to 200 fewer calories per day than someone who weighs the same but never lost weight.

1. Non-exercise activity thermogenesis (NEAT) decreases. You unconsciously move less. Fidgeting, posture shifts, walking pace all slow down. This accounts for another 100 to 150 calories per day (Rosenbaum et al., Journal of Clinical Investigation, 2008).

1. Appetite hormones partially recover. Ghrelin (the hunger hormone) starts rising again after 6 months of calorie restriction, even on GLP-1 medication. Leptin (the satiety hormone) remains suppressed. The result is increased hunger despite continued medication (Sumithran et al., New England Journal of Medicine, 2011).

The combination means the calorie deficit that produced 1 pound per week of loss at month 3 now produces 0.2 pounds per week at month 7. You haven't changed behavior. Your body has changed its energy expenditure.

How to break through the plateau:

• Increase protein intake to 1.2 to 1.6 grams per kilogram of body weight. Protein has the highest thermic effect of food (20% to 30% of calories consumed are burned during digestion). Higher protein also preserves lean mass during weight loss, which helps maintain metabolic rate.
• Add resistance training 2 to 3 times per week. Muscle mass is metabolically active tissue. Preserving or building muscle during weight loss counteracts the metabolic rate decrease.
• Do NOT reduce calories further. You're already in a deficit. Cutting calories more triggers additional metabolic adaptation and makes the plateau worse.
• Stay on medication. The plateau is temporary. Patients who stay on tirzepatide through the plateau resume weight loss at 0.3 to 0.5 pounds per week and reach 18% to 22% total loss by month 18.

The plateau typically lasts 6 to 10 weeks. If weight loss has been completely stalled (not just slow) for more than 12 weeks despite adherence, contact your provider. That's outside the normal adaptation window.

Compounded tirzepatide vs brand-name Mounjaro: does timeline differ?

Compounded tirzepatide contains the same active ingredient as brand-name Mounjaro (tirzepatide). The timeline for weight loss should be comparable if the compounded product is dosed correctly and stored properly.

Two caveats:

1. Dosing precision. Compounded tirzepatide is typically provided as a lyophilized powder that you or a pharmacist reconstitutes with bacteriostatic water. If reconstitution is done incorrectly (wrong volume of water, inadequate mixing), the effective dose per injection may be lower than intended. This would delay results. Brand-name Mounjaro comes in pre-filled single-dose pens with guaranteed dose accuracy.

1. Stability. Tirzepatide degrades at room temperature. Compounded vials must be refrigerated continuously after reconstitution. If a vial is left out for more than 2 hours, potency drops. Brand-name pens are more stable and tolerate brief temperature excursions better.

If you're using compounded tirzepatide and your timeline is lagging behind the benchmarks above, verify:

• Reconstitution was done with the correct volume of bacteriostatic water
• The vial has been refrigerated continuously
• You're injecting the correct volume per dose (use an insulin syringe with 0.01 mL markings, not a 1 mL syringe)

FormBlends provides reconstitution instructions and dose calculators with every compounded tirzepatide prescription to minimize dosing errors.

The decision tree: interpreting your personal timeline

Use this decision tree to interpret whether your timeline is on track or requires intervention.

At week 8:

• Lost 3% or more of body weight → Continue current dose escalation schedule
• Lost 1% to 3% of body weight → Verify medication storage and injection technique, continue current schedule
• Lost less than 1% of body weight → Contact provider to discuss accelerated titration or dose verification

At week 16:

• Lost 5% or more of body weight → On track for 15%+ total loss, continue current dose
• Lost 3% to 5% of body weight → Slower responder, consider escalating to next dose tier if not already at 15 mg
• Lost less than 3% of body weight → Low responder, provider evaluation for secondary causes (thyroid, medications, adherence barriers)

At week 24:

• Lost 8% or more of body weight → Excellent response, expect plateau phase soon, prepare mentally
• Lost 5% to 8% of body weight → Moderate response, continue current dose, add resistance training
• Lost less than 5% of body weight → Non-responder threshold, discuss dose escalation to 15 mg or switch to combination therapy

At week 40:

• Weight stable or slowly declining → Plateau adaptation phase, normal, stay on medication
• Weight regaining → Possible medication adherence issue, metabolic adaptation, or return of binge eating, provider evaluation needed
• Still losing 1+ pounds per week → High responder, expect stabilization soon

[Diagram suggestion: Flowchart-style decision tree with yes/no branches based on weight loss percentage at each checkpoint, leading to specific action recommendations]

Factors that accelerate or delay results

Factors that accelerate weight loss:

• Higher starting BMI. Patients with BMI over 35 lose weight faster in absolute pounds (though similar percentage) compared to patients with BMI 27 to 30.
• Male sex. Men lose weight 15% to 20% faster than women on average, likely due to higher baseline metabolic rate and lean mass.
• Younger age. Patients under 45 lose weight faster than patients over 55, though total weight loss at 72 weeks is similar.
• No prior GLP-1 use. Treatment-naive patients respond faster than patients switching from semaglutide.
• Concurrent resistance training. Preserves lean mass and maintains metabolic rate during calorie deficit.
• High protein intake (1.2 to 1.6 g/kg/day). Increases thermic effect of food and preserves muscle.

Factors that delay weight loss:

• Hypothyroidism. Even subclinical hypothyroidism (TSH 4.5 to 10) reduces metabolic rate by 5% to 8%. Get thyroid function tested if weight loss stalls.
• Medications that cause weight gain. Antipsychotics (olanzapine, quetiapine), antidepressants (mirtazapine, paroxetine), mood stabilizers (valproate, lithium), beta blockers (metoprolol), and corticosteroids all counteract GLP-1 weight loss.
• Insulin resistance. Patients with HbA1c over 6.0% or fasting insulin over 15 mIU/L lose weight slower. Adding metformin can help.
• Sleep deprivation. Less than 6 hours per night increases ghrelin and reduces leptin sensitivity, counteracting appetite suppression.
• High stress and cortisol. Chronic stress increases cortisol, which promotes visceral fat retention and reduces GLP-1 effectiveness.
• Alcohol consumption. Alcohol provides 7 calories per gram (nearly as much as fat) and is not suppressed by GLP-1-mediated appetite reduction. Patients who drink 3+ drinks per week lose 20% to 25% less weight than non-drinkers.

When a thoughtful clinician might recommend stopping Mounjaro despite weight loss

Most articles frame Mounjaro as universally beneficial if you're losing weight. But there are scenarios where continuing treatment is the wrong choice, even if the scale is moving.

Scenario 1: Disordered eating patterns emerge.

Some patients respond to GLP-1-induced appetite suppression by developing restrictive eating patterns that meet criteria for an eating disorder. If you're eating fewer than 1,000 calories per day, avoiding entire food groups out of fear rather than preference, or experiencing anxiety around meals, the medication may be unmasking or worsening an underlying eating disorder. Weight loss in this context is not healthy weight loss.

Scenario 2: Lean mass loss exceeds 30% of total weight loss.

Healthy weight loss is 70% to 75% fat mass and 25% to 30% lean mass. If you're losing muscle disproportionately (detectable via DEXA scan or bioimpedance), continuing aggressive weight loss weakens you and increases fracture risk. This pattern is more common in older adults and patients who don't do resistance training.

Scenario 3: Gallstone formation.

Rapid weight loss (more than 1.5% of body weight per week) increases gallstone risk. If you develop right-upper-quadrant pain after fatty meals, ultrasound may show gallstones. Continuing tirzepatide while symptomatic gallstones are present increases the risk of cholecystitis and pancreatitis.

Scenario 4: Financial unsustainability.

If continuing Mounjaro or compounded tirzepatide requires financial trade-offs that compromise other aspects of health (skipping other medications, reducing food quality, increased stress), the long-term harm may outweigh the short-term weight loss benefit. A thoughtful clinician discusses sustainability, not just efficacy.

These scenarios are uncommon, but they're the cases where "the medication is working" and "you should stay on the medication" are not equivalent statements.

FAQ

How long does it take to lose weight on Mounjaro? Most patients lose their first 1 to 2 pounds within 7 to 14 days. Clinically meaningful weight loss (5% of body weight) takes 12 to 16 weeks on average. Peak weight loss occurs at 60 to 72 weeks, with median total loss of 15% to 20% depending on maintenance dose.

When will I start seeing results on Mounjaro? Visible results (clothes fitting differently, face looking slimmer) typically appear around week 8 to 12, after you've lost 5% to 8% of body weight. The scale shows results earlier, but physical appearance changes lag by 4 to 6 weeks.

How much weight can I expect to lose in the first month on Mounjaro? The first month is highly variable. Median weight loss is 1.8% of body weight (3 to 4 pounds for a 200-pound patient), but the range is 0 to 10 pounds. The first month is not predictive of long-term results.

Why am I not losing weight on Mounjaro after 4 weeks? Four weeks is too early to assess response. Most patients are still on the 2.5 mg starting dose at week 4, which is subtherapeutic for weight loss. Reassess at week 8. If you've lost less than 2% of body weight by week 8, contact your provider.

Does Mounjaro work faster than Ozempic for weight loss? Tirzepatide (Mounjaro) produces slightly faster weight loss than semaglutide (Ozempic) in head-to-head trials. At week 40, tirzepatide 15 mg produced 12.4% more weight loss than semaglutide 1 mg (SURPASS-2 trial). The timeline to first measurable loss is similar (1 to 2 weeks).

How long does the Mounjaro plateau last? The plateau phase typically lasts 6 to 10 weeks and occurs between weeks 24 and 40 for most patients. Weight loss resumes at a slower rate (0.3 to 0.5 pounds per week) after the plateau if you stay on medication.

Can I lose weight faster by starting at a higher dose of Mounjaro? No. Starting at a higher dose increases nausea and vomiting, which often leads to discontinuation. Patients who start at 2.5 mg and titrate slowly have better adherence and similar total weight loss at 72 weeks compared to accelerated titration.

What happens if I stop Mounjaro after losing weight? Most patients regain 30% to 50% of lost weight within 12 months of stopping tirzepatide. The SURMOUNT-1 extension showed patients who stopped at week 72 regained an average of 7.2% of body weight by week 104. Continued treatment is required to maintain weight loss.

How long do I need to stay on Mounjaro to keep weight off? Current evidence suggests indefinite treatment is needed to maintain weight loss. Obesity is a chronic disease. Stopping GLP-1 medication is similar to stopping blood pressure medication: the underlying condition returns.

Does compounded tirzepatide work as fast as brand-name Mounjaro? Yes, if dosed and stored correctly. Compounded tirzepatide contains the same active ingredient. The timeline should be comparable. If results lag, verify reconstitution accuracy and refrigeration.

Why did I lose 10 pounds in the first 2 weeks then nothing for 3 weeks? The initial rapid loss was likely water weight from glycogen depletion. When glycogen stores refill (which happens if you eat a higher-carb meal), water weight returns temporarily. This is normal and not a sign the medication stopped working.

Is it normal to lose weight slowly on Mounjaro? Yes. The median weight loss at week 8 is only 4.2% of body weight. Slow and steady loss (0.5 to 1 pound per week) is more sustainable and associated with better lean mass preservation than rapid loss.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity: Extension Study. Nature Medicine. 2023.
3. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
4. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2023.
5. Leibel RL et al. Changes in energy expenditure resulting from altered body weight. American Journal of Clinical Nutrition. 1995.
6. Rosenbaum M et al. Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight. Journal of Clinical Investigation. 2008.
7. Sumithran P et al. Long-term persistence of hormonal adaptations to weight loss. New England Journal of Medicine. 2011.
8. Davies MJ et al. Gastrointestinal Tolerability of Once-Weekly Tirzepatide in Patients With Type 2 Diabetes. Diabetes Care. 2023.
9. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
10. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
11. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
12. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. JAMA. 2021.
13. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
14. American College of Gastroenterology. Clinical Guidelines for the Diagnosis and Management of Obesity. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Ozempic, and Wegovy are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.